TD Cowen initiated coverage on DICE Therapeutics
$DICE
Biotechnology: Pharmaceutical Preparations
Health Care
TD Cowen initiated coverage of DICE Therapeutics with a rating of Outperform
Save time and jump to the most important pieces.
Date | Price Target | Rating | Analyst |
---|---|---|---|
5/24/2023 | $38.00 | Equal Weight | Wells Fargo |
5/22/2023 | $71.00 | Buy | Canaccord Genuity |
3/31/2023 | $56.00 | Buy | Needham |
3/1/2023 | Outperform | TD Cowen | |
3/1/2023 | Outperform | Cowen | |
11/15/2022 | $65.00 | Buy | Guggenheim |
9/14/2022 | $36.00 | Overweight | Cantor Fitzgerald |
9/7/2022 | $37.00 | Buy | Stifel |